(Reuters) -AstraZeneca beat third-quarter earnings expectations on Thursday, helped by strong sales of key cancer, heart and kidney disease drugs, prompting London’s most valuable listed company to retain its full-year forecasts.
(Reporting by Pushkala Aripaka and Unnamalai L in Bengaluru, and Maggie Fick in London; Editing by Rashmi Aich)
Brought to you by www.srnnews.com